Tenth patent issued for the ZIP™ family of implants
CARLSBAD, CA, Jan. 8, 2026 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in minimally invasive solutions for spinal and interventional pain, today announced the issuance of two separate U.S. patents by the U.S. Patent and Trademark Office. The issuance of these patents strengthens the intellectual property portfolio of the company and reinforces its long-term innovation strategy across multiple spinal implant platforms.
New US patent issued for the ZIP™ family of implants
The first patent issued was number 12,478,411 B2, titled Spinal Implant for Motion Preservation or Fusion, and represents the tenth US patent issued supporting the ZIP™ family of implants. This patent further expands the protected design space around the most established and clinically adopted Aurora Spine platform.
The patented technology covers a spinal implant architecture designed to support motion preservation or fusion, depending on the clinical application. The design incorporates multiple interacting structural components that distribute load and progressively engage under physiological forces, addressing the limitations of traditional rigid implants while maintaining stability and durability.
“The issuance of the tenth patent for the ZIP family of implants highlights the strength, longevity and originality of this platform,” said Trent J. Northcutt, President and CEO of Aurora Spine. “ZIP has been a foundational technology for our company and this milestone further strengthens our ability to protect and develop solutions that address real-world biomechanical and clinical challenges in spine surgery.”
Third patent for orthopedic implants with results compatible with bone density scanning
Aurora Spine also announced the issuance of US Patent No. 12,478,481 B2, titled Orthopedic Implants and Methods of Use with Results Consistent with Bone Density Scanning. This patent protects a distinct technology focused on selecting orthopedic implants based on the results of a patient’s bone density scan, such as DEXA measurements.
The patented method establishes a structured, data-driven framework that allows surgeons to:
Use objective bone density data to guide implant selection. Match the implant characteristics to the patient’s bone quality. Apply a standardized approach across different bone density profiles.
This technology forms the basis of Aurora Spine’s DEXA Technology™ platform, which represents the company’s third equivalent bone density implant system patent.
“Bone quality is one of the most important variables in spine surgery, but has historically been underutilized in implant selection,” said Laszlo Garamszegi, chief technology officer and co-founder of Aurora Spine. “This patent establishes a formal, repeatable method for aligning implant selection with patient bone characteristics using objective data.”
Strengthening Aurora Spine’s innovation strategy
The same-day issuance of these two patents underscores Aurora Spine’s continued investment in diverse, non-overlapping innovation pathways. Each patent independently supports future product development, clinical differentiation and long-term shareholder value, while reinforcing the company’s reputation for meaningful surgeon-driven innovation.
Both patents are now issued and enforceable in the United States.
About Aurora’s spine
Aurora Spine Corporation (TSXV: ASG) (OTCQB: ASAPF) is an innovative designer and manufacturer of minimally invasive spinal implants and interventional technologies for pain management. Headquartered in Carlsbad, California, the company’s mission is to improve spine surgery outcomes through simplified, integrated and cost-effective solutions that improve patient care worldwide.
Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
This press release contains statements that constitute “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking statements”). Forward-looking statements include, but are not limited to, statements regarding the expected impact of issued patents, future product development, business performance and the company’s strategic objectives.
Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on forward-looking statements. Aurora Spine undertakes no obligation to update or revise any forward-looking statements, except as required by applicable securities laws.
Contacts of companies and investors
Aurora Spine Corporation
Trent J. Northcutt
President and CEO
Telephone: (760) 424-2004
Chad Clouse
CFO
Telephone: (760) 424-2004
Investor Relations
Adam Lowensteiner
Lytham Partners
Telephone: (646) 829-9702
Email: asapf@lythampartners.com
